Loading…
Traws Pharma, Inc. is projected to decline to $1.43 by 2027, a -6% move from its current price of $1.53. TRAW is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.42 | $1.53 | $1.64 | -0.01% |
| May 30 | $1.38 | $1.53 | $1.69 | -0.01% |
| May 31 | $1.35 | $1.53 | $1.73 | -0.02% |
| Jun 1 | $1.33 | $1.53 | $1.76 | -0.02% |
| Jun 2 | $1.30 | $1.53 | $1.79 | -0.03% |
| Jun 3 | $1.29 | $1.53 | $1.82 | -0.03% |
| Jun 4 | $1.27 | $1.53 | $1.85 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.53 | $1.85 | -0.04% |
| Week 2 | $1.17 | $1.53 | $1.99 | -0.08% |
| Week 3 | $1.10 | $1.53 | $2.12 | -0.12% |
| Week 4 | $1.05 | $1.53 | $2.22 | -0.16% |
| Week 5 | $1.00 | $1.53 | $2.32 | -0.20% |
| Week 6 | $0.9631 | $1.53 | $2.42 | -0.24% |
| Week 7 | $0.9279 | $1.53 | $2.51 | -0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company in the Healthcare sector that develops small synthetic molecules for respiratory viral diseases and cancer.
It is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
The company is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies, as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has license agreements with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma, Inc. (TRAW) trades at $1.49 per share and has a market cap of $22.57M. It ranks 4904 by market cap.
The current price outlook is reflected in a year-by-year forecast where near-term results are Neutral to Bearish and long-term results turn Bullish, with an Avg price rising from $1.49 in 2026 to $5.59 in 2050. The forecast indicates a progression from neutral in 2026 to bullish sentiment from 2030 onward, with 2030 Avg at $2.04 and a Max of $3.55.
The near-term technical backdrop shows a bearish tone relative to recent price action, alongside a price near the lower end of historical ranges.
A major floor 62.3% below — a decisive break under it would weaken the trend.
The nearest floor, 25.5% below — buyers have tended to step in here.
The nearest ceiling, 42.5% above — a clean break opens room to run.
A major ceiling 84.3% above — clearing it would confirm fresh momentum.
Key TRAW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.54 | Sell | $1.56 | Sell |
| MA 10 | $1.63 | Sell | $1.60 | Sell |
| MA 20 | $1.64 | Sell | $1.60 | Sell |
| MA 50 | $1.64 | Sell | $1.63 | Sell |
| MA 100 | $1.74 | Sell | $1.72 | Sell |
| MA 200 | $1.89 | Sell | $2.10 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.35 | Neutral |
| Stoch RSI (14) | 5.45 | Buy |
| CCI (20) | -51.08 | Neutral |
| Williams %R (14) | -94.20 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -29.82 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 5.80 | Buy |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 32.58 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 1.48 | Buy |
| ADX (14) | 12.61 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is bearish. RSI14 is 50 and the price sits near the moving averages, with SMA50 at $1.66 and SMA200 at $1.89.
Key support is at $1.14 and resistance at $2.18. The 30-day range spans from a low of $0.914 to a high of $2.43, highlighting notable near-term volatility and potential for short-term moves within this band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $1.53 | $1.79 | 0% | Neutral | |
| $1.03 | $1.43 | $2.16 | -6% | Neutral | |
| $0.9132 | $1.35 | $2.15 | -12% | Neutral | |
| $0.9082 | $1.41 | $2.36 | -8% | Neutral | |
| $1.27 | $2.06 | $3.59 | +35% | Bullish | |
| $1.20 | $2.03 | $3.67 | +33% | Bullish | |
| $1.15 | $2.04 | $3.79 | +33% | Bullish | |
| $1.13 | $2.08 | $3.98 | +36% | Bullish | |
| $0.8076 | $1.55 | $3.03 | +1% | Neutral | |
| $0.936 | $1.87 | $3.74 | +22% | Bullish | |
| $1.15 | $2.55 | $5.61 | +67% | Bullish | |
| $2.48 | $5.51 | $12.67 | +260% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.14 | $1.53 | $1.83 | +0.00% |
| June 2026 | $1.34 | $1.61 | $1.99 | +4.91% |
| July 2026 | $1.25 | $1.52 | $1.94 | -5.18% |
| August 2026 | $1.17 | $1.44 | $1.88 | -5.17% |
| September 2026 | $1.18 | $1.48 | $1.95 | +2.21% |
| October 2026 | $1.14 | $1.43 | $1.92 | -2.78% |
| November 2026 | $1.03 | $1.31 | $1.77 | -8.82% |
| December 2026 | $1.02 | $1.31 | $1.79 | +0.16% |
Click any year to see its month-by-month TRAW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRAW is projected to trade between $1.14 and $1.79, averaging $1.53 — a potential gain of 0% from today's $1.53. A consolidation phase looks the most probable path here.
Traws Pharma, Inc.'s 2027 outlook centres on $1.43, within a $1.03 to $2.16 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. Price action looks broadly range-bound.
By 2028, TRAW could reach as high as $2.15, with a base case around $1.35 and support toward $0.9132 — roughly -12% from $1.53. A consolidation phase looks the most probable path here.
Expect TRAW to range from $0.9082 to $2.36 through 2029. The $1.41 average target implies a -8% move from current prices. That is up +5% on the projected 2028 average. Price action looks broadly range-bound.
The TRAW price prediction for 2030 points to an average of $2.06 (low $1.27, high $3.59) — a potential gain of +35% on today's $1.53. Buyers look set to stay in control over this stretch.
In 2031, TRAW is projected to trade between $1.20 and $3.67, averaging $2.03 — a potential gain of +33% from today's $1.53. That is -1% versus the projected 2030 average. Momentum favours further upside here.
Traws Pharma, Inc.'s 2032 outlook centres on $2.04, within a $1.15 to $3.79 range. That is up 0% on the projected 2031 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TRAW could reach as high as $3.98, with a base case around $2.08 and support toward $1.13 — roughly +36% from $1.53. Momentum favours further upside here.
Expect TRAW to range from $0.8076 to $3.03 through 2034. The $1.55 average target implies a +1% move from current prices. That is -26% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The TRAW price prediction for 2035 points to an average of $1.87 (low $0.936, high $3.74) — a potential gain of +22% on today's $1.53. Momentum favours further upside here.
In 2040, TRAW is projected to trade between $1.15 and $5.61, averaging $2.55 — a potential gain of +67% from today's $1.53. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Traws Pharma, Inc.'s 2050 outlook centres on $5.51, within a $2.48 to $12.67 range. That is up +116% on the projected 2040 average. That marks a +260% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TRAW today (≈ 653.594771 TRAW) could be worth
$3,601.51
+$2,601.51 (+260%) by 2050 · US Dollar
Based on the average projected TRAW price of $5.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAWwould be worth at today's price.
$1,000 invested in TRAW on May 27, 2025 (≈ 714.285726 TRAW) would be worth
$1,092.86
+$92.86 (+9.3%) today · 1.09× · US Dollar
Based on a TRAW entry price of $1.4 vs. today's $1.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.62 | $944.44 | -5.6% |
| 1 month ago | $1.14 | $1,342.11 | +34.2% |
| 3 months ago | $1.62 | $944.44 | -5.6% |
| 6 months ago | $2.7 | $566.67 | -43.3% |
| 1 year ago | $1.4 | $1,092.86 | +9.3% |
| All time (5.0y) ago | $161.75 | $9.46 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAW forecast.
Our base-case forecast reaches $3.10 around 2050.
Implied market cap at $3.10: $46.97M
From 2030 onward, the price outlook becomes more constructive. In 2030 the Avg is $2.04 with a Max of $3.55 and a Min of $1.25, yielding a 36.6 (ROIPct) with bullish sentiment. The trajectory through 2031–2033 remains bullish with Avg values around $2.00–$2.04 and Max values near $3.90, accompanied by ROI figures in the mid-30s.
By 2040, the forecast shows an Avg of $2.51, a Max of $5.51, and an ROI of 68.2, with bullish sentiment continuing. By 2050, the Avg reaches $5.59, the Max $12.85, and an ROI of 275, with sentiment remaining bullish.
The forecast is accompanied by an implied high volatility, with annualized volatility at 100%, underscoring substantial price swings and uncertainty around long-term outcomes.
Tap a question to reveal the answer.
In 2030 the Avg is $2.04, the Min is $1.25, and the Max is $3.55, with an ROI of 36.6 and bullish sentiment.
The near term shows Neutral sentiment (2026 with Avg $1.49 and ROI 0) and some years with Neutral to Bearish views, but from 2030 onward the outlook is Bullish with higher Avg values and positive ROI (e.g., 2030 Avg $2.04, ROI 36.6; 2050 Avg $5.59, ROI 275). These are estimates and not guarantees.
Yes. The 2030 Max is $3.55, which exceeds $3, indicating a potential to surpass that level in the forecast horizon.
Current price is $1.49 per share and market cap is $22.57M.
The 30-day picture shows Bearish sentiment, RSI14 at 50, SMA50 at $1.66, SMA200 at $1.89, with support at $1.14 and resistance at $2.18. The 30-day range is $0.914 to $2.43.
Traws Pharma, Inc. Community Discussion
0Share your Traws Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.